ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Efficient"

  • Abstract Number: 2831 • 2019 ACR/ARP Annual Meeting

    Cracks in Your Referral Process? Find Your Sustainable Solution Here

    Sheetal Vora1, Amanda Moyer 2, Lynn Kalhagen 2, Anna Sherrod 2, Thomas Griffin 2, Kristen Corcoran 2, Sarah Mabus 2 and Talia Buitrago 2, 1Atrium Health, Charolotte, 2Atrium Health, Charlotte

    Background/Purpose: Early diagnosis for rheumatic conditions is crucial for children to achieve the best functional outcomes. Access to care is difficult due to the volume…
  • Abstract Number: 2520 • 2018 ACR/ARHP Annual Meeting

    Efficacy of the Reference Biologic Agents in Two Different Types of Randomized Clinical Trials: 1/ the Ones Comparing Their Efficacy Vs. Placebo and 2/ the Ones Comparing Their Efficacy Vs. Biosimilar in Rheumatoid Arthritis: A Systematic Review of Literature and Meta-Analysis

    Lea Lopez1, Christophe Richez2, Marie-Elise Truchetet2, Bernard Bannwarth3, Thomas Barnetche4 and Thierry Schaeverbeke5, 1Aquitaine, Bordeaux, Bordeaux, France, 2Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, 3Rheumatology, CHU de Bordeaux, Bordeaux, France, 4Rheumatology, Centre hospitalier universitaire de Bordeaux - Service de Rhumatologie, Bordeaux, France, 5Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France

    Background/Purpose: Recent randomized clinical trials (RCTs) have shown similar efficacy of biosimilar agents compared to reference agents. Is the efficacy of reference biologic agents different…
  • Abstract Number: 803 • 2018 ACR/ARHP Annual Meeting

    Treating Interstitial Lung Disease and Skin Involvement in Systemic Sclerosis with Oral Versus Intravenous Cyclophosphamide: Preliminary Efficacy and Safety Data from 2 Randomized Clinical Trials and 1 Registry

    Cosimo Bruni1, Donald P. Tashkin2, Virginia D. Steen3, Yannick Allanore4, Oliver Distler5, Jonathan Grotts6, Marco Matucci-Cerinic7 and Daniel E. Furst8, 1Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, 2University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 3Rheumatology, MedStar Georgetown University Hospital, Washington, DC, 4Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, 5Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 6Biostatistics, University of California Los Angeles, Los Angeles, CA, 7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 8University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Two randomized controlled trials showed modest but significant effects for oral (po) CYC ( superior to placebo and  equal to mycophenolate mofetil). A number…
  • Abstract Number: 540 • 2017 ACR/ARHP Annual Meeting

    Being Elderly Is Not a Predictive Factor of Discontinuation of Abatacept Due to Adverse Events in Rheumatoid Arthritis Patients with Concomitant Methotrexate: A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study

    Nobunori Takahashi, Toshihisa Kojima, Shuji Asai, Tatsuo Watanabe, Takuya Matsumoto, Nobuyuki Asai, Yasumori Sobue and Naoki Ishiguro, Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose: Abatacept is a new class of biologic agent for the treatment of rheumatoid arthritis (RA) that inhibits T cell activation by binding to CD80/86.…
  • Abstract Number: 622 • 2017 ACR/ARHP Annual Meeting

    Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study

    Laura C Coates1, Peter Nash2, Tore Kvien3, Laure Gossec4, Philip J Mease5, Lawrence Rasouliyan6, Luminita Pricop7, Steffen Jugl8, Kunal Gandhi7, Corine Gaillez8 and Josef S. Smolen9, 1University of Oxford, Leeds, Great Britain, 2University of Queensland, Brisbane, Australia, 3Diakonhjemmet Hospital, Oslo, Norway, 4UPMC, University Paris 06, Pitié-Salpétrière Hospital, Paris, France, 5Swedish Medical Center and University of Washington, Seattle, WA, 6RTI Health Solutions, Barcelona, Spain, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Pharma AG, Basel, Switzerland, 9Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria

    Background/Purpose: Very low disease activity (VLDA) or remission (REM) and alternatively, minimal disease activity (MDA) or low disease activity (LDA) are optimal targets to be…
  • Abstract Number: 1048 • 2017 ACR/ARHP Annual Meeting

    Efficacy of Educating Visiting Pharmacists Regarding Drug Administration for Patients with Rheumatoid Arthritis Who Poorly Adhere to Treatment Regimens

    Masatoshi Hayashi1, Hiroyuki Matsubara2, Kei Funamura1, Masataka Maeda1 and Toshihisa Kanamono1, 1Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, 2Orthopaedics, Hekinan municipal hospital, Hekinann, Japan

    Background/Purpose: Patients with rheumatoid arthritis (RA) need to take lifelong oral or injectable medication to alleviate their symptoms and prevent disease progression. However, some patients…
  • Abstract Number: 2494 • 2017 ACR/ARHP Annual Meeting

    Analysis of the Efficacy, Safety and Continuation Rate of Abatacept in Elderly Patients with Rheumatoid Arthritis

    Mayumi Matsuda1, Yu Funakubo Asanuma2, Noritsune Kouzu3 and Toshihide Mimura2, 1Department of Rheumatology and Applied Immunology, Saitama Medical University, Moroyama-machi, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 3Saitama Medical University, Moroyama, Japan

    Background/Purpose: The elderly rheumatoid arthritis (RA) patients have declined physical performances and various complications. The efficacy of the biological DMARDs may decrease in elderly RA…
  • Abstract Number: 2904 • 2017 ACR/ARHP Annual Meeting

    Efficacy and Tolerance of TNF Alpha Inhibitor (TNFI) Treatment in Cardiac Sarcoidosis (CS)

    Deborah Puyraimond-Zemmour1, Catherine Chapelon-Abric2, David Saadoun3, Diane Bouvry4, Marc Ruivard5, Marc Andre6, Laurent Perard7, Pascal Sève8 and Patrice Cacoub9, 1Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France, Paris, France, 2AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, 3Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France, 4Hopital Avicenne, Department of Pneumology, Bobigny, France, Bobigny, France, 5CHU Estaing, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, 6CHU Montpied, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, 7Department of Internal Medicine, Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France, 8Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 9Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

    Background/Purpose: CS is a life-threatening condition that accounts for 85% of sarcoidosis-related deaths in Japan and 13-25% in America. The objective is to evaluate the…
  • Abstract Number: 2054 • 2016 ACR/ARHP Annual Meeting

    Effect of Temporary Methotrexate Discontinuation on Efficacy of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomized Clinical Trial

    Jin Kyun Park1, Min Ah Lee Lee2, Kyung Hee Lee2, Eun Young Lee1, Yeong Wook Song3, Yunhee Choi4, Kevin L. Winthrop5 and Eun Bong Lee6, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 2Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, The Republic of, 3Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea, 4Division of Medical Statistics, Medical Research Collaborating Center, Seoul National University College of Medicine, Seoul, Korea, The Republic of, 5Oregon Health and Sciences University, Portland, OR, 6Seoul National University, Seoul, Korea, Republic of

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at a higher risk of infection due to the underlying immune dysfunction and immune suppression associated with treatment.…
  • Abstract Number: 2757 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients

    Hélène Vallet1, Sophie Rivière2, Alban Deroux3, Guillaume Moulis4, Olga Addimanda5, Carlo Salvarani6, Marc Lambert7, Philip Bielfeld8, Pascal Sève9, Jean Sibilia10, Jean Baptiste Fraison11, Yoland Schoindre12, Isabelle Marie13, Laurent Perard14, Thomas Papo15, Damien Sène16, Gaelle Leroux17, Valerie Royant18, Antoinette Perlat19, Xavier Mariette20, Olivier Lidove21, Olivier Fain22, Claire De Moreuil23, Gilles Blaison24, Phuc LE Hoang25, Eric Hachulla26, Bertrand Wechsler27, Barham Bodaghi28, Patrice Cacoub29 and David Saadoun30, 1Internal medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, 2Internal Medicine, Lapeyronie, Montpellier, France, 3Internal Medicine, CHU Grenoble, Grenoble, France, 4Internal Medicine department, Toulouse, Toulouse, France, 5S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, 6Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 7CHRU Lille, Lille, France, 8CHU de Dijon, Dijon, France, 9Internal medicine, CHU Lyon, Lyon, France, 10Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, 11Hôpital Jean Verdier, Bondy, France, 12DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, PARIS, France, 13CHU de Rouen, Rouen, France, 14Hospices civils de Lyon, Lyon, France, 15Hôpital Bichat, Paris, France, 16Hopital Lariboisière, service de Médecine Interne, Paris, France, 17Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, 18Chartres, Chartres, France, 19Internal medicine, CHU de Rennes, Rennes, France, 20rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, 21Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, 22Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, 23CHU, Brest, France, 24Internal medicine, CHR, Colmar, France, 25Ophtalmology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpétrière, Paris, France, 26Internal Medicine, National Scleroderma Centre, Lille CEDEX, France, 27Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, 28Ophtalmology, Hôpital de la Pitié Salpêtrière, Paris, France, 29Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, 30DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France

    Background/Purpose Behçet’s disease (BD) is a systemic large vessel vasculitis with recurrent genital and oral ulceration, uveitis, cardiovascular, joints, neurological or gut symptoms. Treatment of…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology